Switzer Daily
15 December 2020
Last week, Creso Pharma Limited’s (ASX: CPH; FRA: 1X8) wholly-owned Canadian cannabis cultivation subsidiary, Mernova Medicinal Inc. received three purchase orders with a combined value of C$275,023 (A$288,159).
These new purchase orders
are part of a trend this year, which has seen CPH
generate more consistent revenue through product demand, whilst substantially
trimming operating costs.
The first of the new
purchase orders was
valued at C$232,826 (A$243,841) and came from Truro Cannabis Company, a
licensed producer of medical and recreational cannabis products.
The Truro order is a bulk order for three of
Mernova’s high quality, indoor grown, hand trimmed, hang dried, cured,